560 related articles for article (PubMed ID: 19920223)
1. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
Basch E; Jia X; Heller G; Barz A; Sit L; Fruscione M; Appawu M; Iasonos A; Atkinson T; Goldfarb S; Culkin A; Kris MG; Schrag D
J Natl Cancer Inst; 2009 Dec; 101(23):1624-32. PubMed ID: 19920223
[TBL] [Abstract][Full Text] [Related]
2. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.
Quinten C; Maringwa J; Gotay CC; Martinelli F; Coens C; Reeve BB; Flechtner H; Greimel E; King M; Osoba D; Cleeland C; Ringash J; Schmucker-Von Koch J; Taphoorn MJ; Weis J; Bottomley A
J Natl Cancer Inst; 2011 Dec; 103(24):1851-8. PubMed ID: 22157640
[TBL] [Abstract][Full Text] [Related]
3. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
Basch E; Iasonos A; McDonough T; Barz A; Culkin A; Kris MG; Scher HI; Schrag D
Lancet Oncol; 2006 Nov; 7(11):903-9. PubMed ID: 17081915
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
[TBL] [Abstract][Full Text] [Related]
5. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
Basch E; Wood WA; Schrag D; Sima CS; Shaw M; Rogak LJ; Kris MG; Shouery M; Bennett A; Atkinson T; Pietanza MC
Clin Trials; 2016 Jun; 13(3):331-7. PubMed ID: 26542025
[TBL] [Abstract][Full Text] [Related]
7. Patient symptoms and clinician toxicity ratings: both have a role in cancer care.
Gotay C
J Natl Cancer Inst; 2009 Dec; 101(23):1602-3. PubMed ID: 19920222
[No Abstract] [Full Text] [Related]
8. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.
Basch E; Iasonos A; Barz A; Culkin A; Kris MG; Artz D; Fearn P; Speakman J; Farquhar R; Scher HI; McCabe M; Schrag D
J Clin Oncol; 2007 Dec; 25(34):5374-80. PubMed ID: 18048818
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
10. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
11. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Zhong X; Lim EA; Hershman DL; Moinpour CM; Unger J; Lee SM
J Oncol Pract; 2016 Mar; 12(3):e270-80, 245-6. PubMed ID: 26907453
[TBL] [Abstract][Full Text] [Related]
12. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.
Cirillo M; Venturini M; Ciccarelli L; Coati F; Bortolami O; Verlato G
Ann Oncol; 2009 Dec; 20(12):1929-35. PubMed ID: 19622510
[TBL] [Abstract][Full Text] [Related]
13. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
15. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
[TBL] [Abstract][Full Text] [Related]
16. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
17. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
[TBL] [Abstract][Full Text] [Related]
19. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
20. Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.
Nyrop KA; Deal AM; Reeve BB; Basch E; Chen YT; Park JH; Shachar SS; Carey LA; Reeder-Hayes KE; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Lee JT; Wood WA; Muss HB
Cancer; 2020 Jul; 126(13):3084-3093. PubMed ID: 32315091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
